Drug
HM15912
HM15912 is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_1
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
NCT05711381
completedphase_1
Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects
NCT04076293
Clinical Trials (2)
Showing 2 of 2 trials
NCT05711381Phase 1
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
NCT04076293Phase 1
Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2